MARKET

AEZS

AEZS

Aeterna Zentaris Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.2050
-0.0111
-5.14%
Pre Market: 0.2000 -0.005 -2.44% 05:56 07/06 EDT
OPEN
0.2160
PREV CLOSE
0.2161
HIGH
0.2233
LOW
0.1954
VOLUME
2.70K
TURNOVER
--
52 WEEK HIGH
0.9750
52 WEEK LOW
0.1645
MARKET CAP
24.89M
P/E (TTM)
-2.6015
1D
5D
1M
3M
1Y
5Y
Aeterna Zentaris Announces Results of Annual Meeting of Shareholders
- Vote to approve share consolidation adjourned to July 6, 2022 TORONTO, ONTARIO, June 21, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commerci...
GlobeNewswire · 06/21 20:01
21 Stocks Moving in Friday's Pre-Market Session
Gainers Athersys, Inc. (NASDAQ: ATHX) rose 48.5% to $0.4755 in pre-market trading after dropping more than 12% on Thursday.
Benzinga · 06/17 09:51
BRIEF-Aeterna Zentaris Achieves Proof-Of-Concept For The Treatment Of Nmosd With Aim Biologicals Program
reuters.com · 06/13 12:25
Aeterna Zentaris Achieves Proof-of-Concept for the Treatment of NMOSD with AIM Biologicals Program
– Company advancing AIM Biologicals development program as a potential therapeutic treatment option for neuromyelitis optica spectrum disorder ("NMOSD") – Positive results presented at the 13th International Congress on Autoimmunity being held in Athens, G...
GlobeNewswire · 06/13 12:00
Aeterna Zentaris to Present at the JMP Securities Life Sciences Conference
Live video webcast on Wednesday, June 15th at 12:30 PM ET TORONTO, ONTARIO, June 09, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializin...
GlobeNewswire · 06/09 12:00
Here's Why We're Watching Aeterna Zentaris' (TSE:AEZS) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Simply Wall St. · 06/03 10:58
Aeterna Zentaris licensing partner Consilient launches growth hormone deficiency test in Europe
Aeterna Zentaris (NASDAQ:AEZS) said its licensing partner Consilient Health launched Ghryvelin, an oral test for diagnosing growth hormone deficiency in adults, in Europe. The company said Ghryvelin  (macimorelin) was approved in European in 2019, backed
Seekingalpha · 05/25 12:57
Aeterna Zentaris' Licensing Partner, Consilient Health Announces European Launch Of Ghryvelin For Diagnosing Adult Growth Hormone Deficiency
Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and
Benzinga · 05/25 12:08
More
No Data
Learn about the latest financial forecast of AEZS. Analyze the recent business situations of Aeterna Zentaris Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average AEZS stock price target is 1.500 with a high estimate of 1.500 and a low estimate of 1.500.
High1.500
Average1.500
Low1.500
Current 0.2050
EPS
Actual
Estimate
-0.02-0.02-0.01-0.01
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 38
Institutional Holdings: 1.49M
% Owned: 1.22%
Shares Outstanding: 121.40M
TypeInstitutionsShares
Increased
5
73.08K
New
2
6.16K
Decreased
8
395.17K
Sold Out
7
285.26K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.07%
Pharmaceuticals & Medical Research
+0.40%
Key Executives
Non-Executive Chairman/Independent Director
Carolyn Egbert
President/Chief Executive Officer/Director
Klaus Paulini
Chief Financial Officer/Senior Vice President
Giuliano La Fratta
Senior Vice President/Managing Director
Eckhard Gunther
Senior Vice President
Nicola Ammer
Senior Vice President
Matthias Gerlach
Independent Director
Peter Edwards
Independent Director
Gilles Gagnon
Independent Director
Dennis Turpin
No Data
No Data
About AEZS
Aeterna Zentaris Inc. is a specialty biopharmaceutical company. The Company is focused on developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. Its business is to finalize the development, manufacturing, registration and commercialization of Macrilen (macimorelin). Macrilen (macimorelin) is an orally available peptidomimetic ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the ghrelin receptor (GHSR-1a) and that has potential uses in both endocrinology and oncology indications. Macimorelin is the oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is leveraging the clinical and compelling safety profile of macimorelin in developing diagnosis of childhood-onset growth hormone deficiency (CGHD) in collaboration with Novo Nordisk.

Webull offers kinds of AEterna Zentaris Inc. (USA) stock information, including NASDAQ:AEZS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AEZS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AEZS stock methods without spending real money on the virtual paper trading platform.